LVTX May 2024 2.500 call
| Previous close | 0.4000 |
| Open | 0.4000 |
| Bid | 0.0000 |
| Ask | 0.2000 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.4000 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 419 |
Globe NewswireLAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Citizens JMP Life Sciences Conference. Presentation Details Format: Fireside
Simply Wall St.LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint
LAVA Therapeutics ( NASDAQ:LVTX ) Full Year 2023 Results Key Financial Results Net loss: US$42.0m (loss widened by 32...
- Globe Newswire
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for EGFRd2 (PF-08046052/formerly LAVA-1223) LAVA 1266 tracking to Q2 2024 IND submission Strong balance sheet with cash of $95.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage
